Boehringer Ingelheim is conducting a clinical trial of a new obesity treatment in Korea. It is noteworthy whether it will exceed the sales of Saxenda (Liraglutide·NovoNordisk), which is currently leading in the Korean market.

The MFDS approved the Phase II clinical trial protocol of BI 456906, a candidate for the new obesity drug of Boehringer Ingelheim on the 4th.

This clinical trial is a 46-week trial that is administered subcutaneously once a week compared to placebo in obese or overweight patients.

As a multinational clinical trial, 16 patients participate in Korea. The total number of subjects is 350.

This drug is known as a candidate for a new drug obt